Burkitt Lymphoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Burkitt Lymphoma | Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine | FDA |
| Sensitivity (+) | t(KMT2A;v) | Burkitt Lymphoma | Revumenib | FDA |
| Sensitivity (+) | NPM1 p.W288Cfs*12 | Burkitt Lymphoma | Revumenib | FDA |